Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Razelle Kurzrock

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0658
    CA La Jolla 92093
    Phone858-246-1102
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 Jun; 22(6):631-637. PMID: 28550027.
        View in: PubMed
      2. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen EEW, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Apr 18. PMID: 28420725.
        View in: PubMed
      3. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 Feb 13. PMID: 28194539.
        View in: PubMed
      4. Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. Mol Cancer Ther. 2017 Feb; 16(2):265-272. PMID: 28159915.
        View in: PubMed
      5. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Jan 19. PMID: 28103611.
        View in: PubMed
      6. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Jan 13. PMID: 28087540.
        View in: PubMed
      7. Kurzrock R, Stewart DJ. Exploring the Benefit/Risk Associated With Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2016 Dec 09. PMID: 27940520.
        View in: PubMed
      8. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors. JAMA Oncol. 2016 Dec 01; 2(12):1565-1573. PMID: 27388585.
        View in: PubMed
      9. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2016 Nov 23. PMID: 27893038.
        View in: PubMed
      10. Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2016 Nov 21. PMID: 27873079.
        View in: PubMed
      11. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res. 2016 Nov 16. PMID: 27852698.
        View in: PubMed
      12. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2016 Nov 4; 52:12-21. PMID: 27883925.
        View in: PubMed
      13. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2016 Nov 02. PMID: 27805626.
        View in: PubMed
      14. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 1; 2(11):1452-1459. PMID: 27273579.
        View in: PubMed
      15. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. PMID: 27942391.
        View in: PubMed
      16. Le Tourneau C, Kurzrock R. Targeted therapies: What have we learned from SHIVA? Nat Rev Clin Oncol. 2016 Oct 11. PMID: 27725677.
        View in: PubMed
      17. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2016 Sep 28. PMID: 27683183.
        View in: PubMed
      18. Janku F, Kurzrock R. Bringing Blood-Based Molecular Testing to the Clinic. Clin Cancer Res. 2016 Nov 15; 22(22):5400-5402. PMID: 27663595.
        View in: PubMed
      19. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2016 Sep 7. PMID: 27599876.
        View in: PubMed
      20. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Aug 31. PMID: 27589687.
        View in: PubMed
      21. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 2016 Aug 16; 7(33):53037-53046. PMID: 27419632.
        View in: PubMed
      22. Goodman AM, Choi M, Wang L, Kurzrock R. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 Aug; 30(8). PMID: 27535668.
        View in: PubMed
      23. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 Oct; 15(10):2498-2507. PMID: 27507853.
        View in: PubMed
      24. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Jul 28. PMID: 27486883.
        View in: PubMed
      25. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 Oct; 15(10):2475-2485. PMID: 27466356.
        View in: PubMed
      26. Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 1; 139(9):2135-41. PMID: 27389805.
        View in: PubMed
      27. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 Aug; 15(8):1781-91. PMID: 27413114.
        View in: PubMed
      28. Lam LH, Capparelli EV, Kurzrock R. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 2016 Aug; 78(2):427-32. PMID: 27372908.
        View in: PubMed
      29. Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 2016; 3(5-6):164-72. PMID: 27489863.
        View in: PubMed
      30. Subbiah V, Kurzrock R. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016 Jun 1; 2(6):719-20. PMID: 27078832.
        View in: PubMed
      31. Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 Jun; 35(2):263-75. PMID: 26857926.
        View in: PubMed
      32. Cohen-Kurzrock BA, Cohen PR, Kurzrock R. Health policy: The right to try is embodied in the right to die. Nat Rev Clin Oncol. 2016 Jul; 13(7):399-400. PMID: 27217273.
        View in: PubMed
      33. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 Jun; 15(6):1397-404. PMID: 27207774.
        View in: PubMed
      34. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 Jul 1; 76(13):3690-701. PMID: 27197177.
        View in: PubMed
      35. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
        View in: PubMed
      36. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 Jul; 15(7):1682-90. PMID: 27196769.
        View in: PubMed
      37. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802.
        View in: PubMed
      38. Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget. 2016 Apr 26; 7(17):23454-67. PMID: 26981779.
        View in: PubMed
      39. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res. 2016 Jul; 308(5):357-65. PMID: 27098388.
        View in: PubMed
      40. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 May; 77(5):1097-102. PMID: 27085994.
        View in: PubMed
      41. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016 Apr 12; 7(15):20293-304. PMID: 26934122.
        View in: PubMed
      42. Cohen PR, Kurzrock R. My personal experiences at the BEST Medical Center: A day in the clinic-the morning. Clin Dermatol. 2016 May-Jun; 34(3):422-5. PMID: 27265082.
        View in: PubMed
      43. Cohen PR, Kurzrock R. My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon. Clin Dermatol. 2016 Jul-Aug; 34(4):517-20. PMID: 27343967.
        View in: PubMed
      44. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 Aug; 108(8). PMID: 27059373.
        View in: PubMed
      45. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. PMID: 26994910.
        View in: PubMed
      46. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 Apr; 15(4):533-47. PMID: 27009213.
        View in: PubMed
      47. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr; 3(4):e163-75. PMID: 27063975.
        View in: PubMed
      48. Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 8; 7(10):11310-20. PMID: 26824502.
        View in: PubMed
      49. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 1; 7(9):9707-17. PMID: 26848768.
        View in: PubMed
      50. Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar; 16(1):45-52. PMID: 26689566.
        View in: PubMed
      51. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Response. J Natl Cancer Inst. 2016 Mar; 108(3). PMID: 26912651.
        View in: PubMed
      52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr; 15(4):743-52. PMID: 26873727.
        View in: PubMed
      53. Kurzrock R, Stewart DJ. Click chemistry, 3D-printing, and omics: the future of drug development. Oncotarget. 2016 Jan 19; 7(3):2155-8. PMID: 26734837.
        View in: PubMed
      54. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. PMID: 26698868.
        View in: PubMed
      55. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34. PMID: 26503473.
        View in: PubMed
      56. Fajgenbaum DC, Kurzrock R. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy. 2016 Jan; 8(1):17-26. PMID: 26634298.
        View in: PubMed
      57. Munoz J, Wheler J, Kurzrock R. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Rev. 2015 Dec; 34(4):547-61. PMID: 25543191.
        View in: PubMed
      58. Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e579-80. PMID: 26678197.
        View in: PubMed
      59. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. PMID: 26603258.
        View in: PubMed
      60. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185. PMID: 26582900.
        View in: PubMed
      61. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 2015 Nov 2; 14(21):3434-40. PMID: 26467427.
        View in: PubMed
      62. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015 Nov; 13(11):1337-46. PMID: 26553764.
        View in: PubMed
      63. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953.
        View in: PubMed
      64. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015; 15(1):713. PMID: 26474549.
        View in: PubMed
      65. Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clin Cancer Res. 2015 Oct 15; 21(20):4561-8. PMID: 26473192.
        View in: PubMed
      66. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015 Oct 6; 6(30):30408-19. PMID: 26327301.
        View in: PubMed
      67. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085.
        View in: PubMed
      68. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075.
        View in: PubMed
      69. Kurzrock R. Targeted Inhibitors: Novel Strategies for Response Optimization. Semin Oncol. 2015 Dec; 42(6):773-4. PMID: 26615124.
        View in: PubMed
      70. Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec; 42(6):832-48. PMID: 26615129.
        View in: PubMed
      71. Liu S, Kurzrock R. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Semin Oncol. 2015 Dec; 42(6):863-75. PMID: 26615131.
        View in: PubMed
      72. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. PMID: 26247885.
        View in: PubMed
      73. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31. PMID: 26392102.
        View in: PubMed
      74. Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224.
        View in: PubMed
      75. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159.
        View in: PubMed
      76. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 1; 22(1):259-67. PMID: 26373574.
        View in: PubMed
      77. Schwaederle M, Kurzrock R. Actionability and precision oncology. Oncoscience. 2015; 2(10):779-80. PMID: 26682241.
        View in: PubMed
      78. Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. PMID: 26224133.
        View in: PubMed
      79. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. PMID: 26304871.
        View in: PubMed
      80. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. PMID: 26243651.
        View in: PubMed
      81. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706. PMID: 26155941.
        View in: PubMed
      82. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. PMID: 26210681.
        View in: PubMed
      83. Kurzrock R, Giles FJ. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle. 2015 Jul 18; 14(14):2219-21. PMID: 26030337.
        View in: PubMed
      84. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 1; 21(21):4801-10. PMID: 26169970.
        View in: PubMed
      85. Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. Semin Oncol. 2015 Oct; 42(5):731-9. PMID: 26433554.
        View in: PubMed
      86. Khemlina G, Ikeda S, Kurzrock R. Molecular landscape of prostate cancer: Implications for current clinical trials. Cancer Treat Rev. 2015 Jul 9. PMID: 26210103.
        View in: PubMed
      87. Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. JAMA Oncol. 2015 Jul 1; 1(4):542. PMID: 26181268.
        View in: PubMed
      88. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul; 53(7):563-72. PMID: 26073352.
        View in: PubMed
      89. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. PMID: 26244164.
        View in: PubMed
      90. Ikeda S, Hansel DE, Kurzrock R. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev. 2015 Jun 23. PMID: 26138514.
        View in: PubMed
      91. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. PMID: 25944621.
        View in: PubMed
      92. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632.
        View in: PubMed
      93. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015 Jun 3; 14(11):1730-7. PMID: 25928476.
        View in: PubMed
      94. Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle. 2015 Jul 18; 14(14):2355-61. PMID: 26030731.
        View in: PubMed
      95. Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer. 2015; 15(1):442. PMID: 26021831.
        View in: PubMed
      96. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. PMID: 25990659.
        View in: PubMed
      97. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577.
        View in: PubMed
      98. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015 May 7; 1-8. PMID: 25950492.
        View in: PubMed
      99. Cohen PR, Kurzrock R. The checklist: BEST medical center employment requirements 2015. Clin Dermatol. 2015 Jul-Aug; 33(4):493-7. PMID: 26051067.
        View in: PubMed
      100. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. PMID: 25902899.
        View in: PubMed
      101. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. PMID: 25908602.
        View in: PubMed
      102. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015 Apr 18; 14(8):1252-9. PMID: 25695927.
        View in: PubMed
      103. Falchook GS, Kurzrock R. VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle. 2015 Apr 18; 14(8):1129-30. PMID: 25845022.
        View in: PubMed
      104. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. PMID: 25878190.
        View in: PubMed
      105. Cohen PR, Kurzrock R. Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. Dermatol Ther (Heidelb). 2015 Jun; 5(2):129-43. PMID: 25876211.
        View in: PubMed
      106. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. PMID: 25852059.
        View in: PubMed
      107. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. Meir Wetzler, MD. Cancer. 2015 Jul 1; 121(13):2106-7. PMID: 25832851.
        View in: PubMed
      108. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. PMID: 25822109.
        View in: PubMed
      109. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. PMID: 25760241.
        View in: PubMed
      110. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7(1):29. PMID: 25806091.
        View in: PubMed
      111. Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015 Mar 10; 6(7):4553-61. PMID: 25714017.
        View in: PubMed
      112. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar; 34(1):157-64. PMID: 25712293.
        View in: PubMed
      113. Mohammed A, Janku F, Qi M, Kurzrock R. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. J Med Case Rep. 2015; 9(1):45. PMID: 25884809.
        View in: PubMed
      114. Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748.
        View in: PubMed
      115. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015; 15(1):61. PMID: 25886620.
        View in: PubMed
      116. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr; 14(4):847-56. PMID: 25695955.
        View in: PubMed
      117. Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. J Natl Cancer Inst. 2015 Mar; 107(3). PMID: 25688104.
        View in: PubMed
      118. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. PMID: 25680763.
        View in: PubMed
      119. Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Res. 2015 Apr 1; 75(7):1187-90. PMID: 25672981.
        View in: PubMed
      120. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. PMID: 25666183.
        View in: PubMed
      121. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-8. PMID: 25669829.
        View in: PubMed
      122. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb; 19(103):109-16. PMID: 25725225.
        View in: PubMed
      123. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb; 19(103):101-8. PMID: 25725224.
        View in: PubMed
      124. Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015 Jan 20; 6(2):592-603. PMID: 25595907.
        View in: PubMed
      125. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888.
        View in: PubMed
      126. Geifman N, Haviv I, Kurzrock R, Rubin E. Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase. J Pers Med. 2014; 4(4):475-88. PMID: 25563458.
        View in: PubMed
      127. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec; 18(101):323-30. PMID: 25549703.
        View in: PubMed
      128. Randall JM, Millard F, Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev. 2014 Dec; 33(4):1109-24. PMID: 25365943.
        View in: PubMed
      129. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18(101):331-9. PMID: 25549704.
        View in: PubMed
      130. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67. PMID: 25525888.
        View in: PubMed
      131. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
        View in: PubMed
      132. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. PMID: 25373733.
        View in: PubMed
      133. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. PMID: 25363205.
        View in: PubMed
      134. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49. PMID: 25361808.
        View in: PubMed
      135. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. PMID: 25323060.
        View in: PubMed
      136. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
        View in: PubMed
      137. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15; 74(24):7181-4. PMID: 25326492.
        View in: PubMed
      138. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discov. 2015 Jan; 5(1):64-71. PMID: 25324352.
        View in: PubMed
      139. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136.
        View in: PubMed
      140. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clin Cancer Res. 2014 Dec 1; 20(23):5956-63. PMID: 25316815.
        View in: PubMed
      141. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD anderson cancer center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784.
        View in: PubMed
      142. Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R. Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. PLoS One. 2014; 9(8):e93676. PMID: 25119929.
        View in: PubMed
      143. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. PMID: 25594061.
        View in: PubMed
      144. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088.
        View in: PubMed
      145. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059.
        View in: PubMed
      146. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clin Cancer Res. 2014 Sep 1; 20(17):4449-58. PMID: 24958809.
        View in: PubMed
      147. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695.
        View in: PubMed
      148. Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014 Jun 15; 5(11):3607-10. PMID: 25003820.
        View in: PubMed
      149. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. PMID: 24919855.
        View in: PubMed
      150. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Invest New Drugs. 2014 Dec; 32(6):1181-7. PMID: 24879333.
        View in: PubMed
      151. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22. PMID: 24931142.
        View in: PubMed
      152. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489.
        View in: PubMed
      153. Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014 Aug; 40(7):883-91. PMID: 24867380.
        View in: PubMed
      154. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890.
        View in: PubMed
      155. Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30. PMID: 24819685.
        View in: PubMed
      156. Munoz J, Janku F, Cohen PR, Kurzrock R. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014 Jul; 89(7):985-96. PMID: 24814521.
        View in: PubMed
      157. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the university of california san diego moores cancer center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821.
        View in: PubMed
      158. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
        View in: PubMed
      159. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
        View in: PubMed
      160. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
        View in: PubMed
      161. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
        View in: PubMed
      162. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900.
        View in: PubMed
      163. Morgan-Linnell SK, Stewart DJ, Kurzrock R. U.s. Food and drug administration inspections of clinical investigators: overview of results from 1977 to 2009. Clin Cancer Res. 2014 Jul 1; 20(13):3364-70. PMID: 24737548.
        View in: PubMed
      164. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823.
        View in: PubMed
      165. Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014 Apr; 34(4):1939-45. PMID: 24692729.
        View in: PubMed
      166. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014; 19(4):426-8. PMID: 24668327.
        View in: PubMed
      167. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014 Jul; 40(6):770-80. PMID: 24656976.
        View in: PubMed
      168. Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2192-204. PMID: 24563479.
        View in: PubMed
      169. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb 1; 12(2):194-203. PMID: 24586081.
        View in: PubMed
      170. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060.
        View in: PubMed
      171. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717.
        View in: PubMed
      172. Anzalone CL, Cohen PR, Kurzrock R, Cortes JE. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J. 2014; 20(1):21242. PMID: 24456946.
        View in: PubMed
      173. Cohen PR, Kurzrock R. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J. 2014; 20(1):21241. PMID: 24456945.
        View in: PubMed
      174. Kurzrock R, Kantarjian H, Stewart DJ. A cancer trial scandal and its regulatory backlash. Nat Biotechnol. 2014 Jan 9; 32(1):27-31. PMID: 24406925.
        View in: PubMed
      175. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73. PMID: 24390424.
        View in: PubMed
      176. Schroeder RD, Angelo LS, Kurzrock R. NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014 Jan; 5(1):67-77. PMID: 24393766.
        View in: PubMed
      177. Tang C, Fontes Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979.
        View in: PubMed
      178. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. PMID: 24335388.
        View in: PubMed
      179. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
        View in: PubMed
      180. Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44. PMID: 24258465.
        View in: PubMed
      181. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125.
        View in: PubMed
      182. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8. PMID: 24190980.
        View in: PubMed
      183. Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013 Dec; 24(12):3004-11. PMID: 24158411.
        View in: PubMed
      184. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239.
        View in: PubMed
      185. Falchook GS, Lippman SM, Bastida CC, Kurzrock R. Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck. 2014 Mar; 36(3):E25-7. PMID: 23852769.
        View in: PubMed
      186. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71. PMID: 24101145.
        View in: PubMed
      187. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809.
        View in: PubMed
      188. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic Arterial Infusion Therapy in Advanced Cancer and Liver-Predominant Disease: The MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
        View in: PubMed
      189. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 1; 19(19):5474-84. PMID: 24089446.
        View in: PubMed
      190. Kurzrock R, Stewart DJ. Equipoise abandoned? Randomization and clinical trials. Ann Oncol. 2013 Oct; 24(10):2471-4. PMID: 24072520.
        View in: PubMed
      191. Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov; 72(5):1089-96. PMID: 24057042.
        View in: PubMed
      192. Al Ustwani O, Kurzrock R, Wetzler M. Genetics on a WHIM. Br J Haematol. 2014 Jan; 164(1):15-23. PMID: 24111611.
        View in: PubMed
      193. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75. PMID: 23963360.
        View in: PubMed
      194. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406.
        View in: PubMed
      195. Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One. 2013; 8(7):e68985. PMID: 23922674.
        View in: PubMed
      196. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013 Dec; 4(4):259-65. PMID: 23893509.
        View in: PubMed
      197. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1; 19(17):4824-31. PMID: 23873691.
        View in: PubMed
      198. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
        View in: PubMed
      199. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. Eur J Radiol. 2013 Oct; 82(10):1811-8. PMID: 23769187.
        View in: PubMed
      200. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764.
        View in: PubMed
      201. Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013 Jul 10; 31(20):e360-3. PMID: 23733774.
        View in: PubMed
      202. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10; 31(20):e351-2. PMID: 23733763.
        View in: PubMed
      203. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. PMID: 23765114.
        View in: PubMed
      204. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9. PMID: 23800680.
        View in: PubMed
      205. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
        View in: PubMed
      206. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 1; 19(13):3659-70. PMID: 23659971.
        View in: PubMed
      207. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712.
        View in: PubMed
      208. Zwelling LA, Kurzrock R, Cohen PR, Levin B, Parish LC. The Karabus affair speaks to larger issues for American academic and medical centers. Clin Dermatol. 2013 May-Jun; 31(3):325-6. PMID: 23608452.
        View in: PubMed
      209. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029.
        View in: PubMed
      210. Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 5; 105(11):833. PMID: 23628598.
        View in: PubMed
      211. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. PMID: 23609829.
        View in: PubMed
      212. Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer. 2013; 13:193. PMID: 23587187.
        View in: PubMed
      213. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709.
        View in: PubMed
      214. Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70. PMID: 23455881.
        View in: PubMed
      215. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6. PMID: 23552670.
        View in: PubMed
      216. Janku F, Huang HJ, Angelo LS, Kurzrock R. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 2013 Mar; 4(3):463-73. PMID: 23531874.
        View in: PubMed
      217. Kurzrock R, Stewart DJ. Compliance in early-phase cancer clinical trials research. Oncologist. 2013; 18(3):308-13. PMID: 23457001.
        View in: PubMed
      218. Naing A, Kurzrock R. Dodging a dogma: is treating beyond progression beneficial? Cancer Chemother Pharmacol. 2013 May; 71(5):1385-6. PMID: 23443308.
        View in: PubMed
      219. Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May; 49(7):1521-9. PMID: 23433846.
        View in: PubMed
      220. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5; 108(4):826-30. PMID: 23412108.
        View in: PubMed
      221. Munoz J, Kurzrock R. Unilateral proptosis. JAMA. 2013 Feb 13; 309(6):605-6. PMID: 23403685.
        View in: PubMed
      222. Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-8. PMID: 23400451.
        View in: PubMed
      223. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. AJR Am J Roentgenol. 2013 Feb; 200(2):W155-62. PMID: 23345379.
        View in: PubMed
      224. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20. PMID: 23328556.
        View in: PubMed
      225. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013 Feb; 4(2):310-5. PMID: 23470635.
        View in: PubMed
      226. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73. PMID: 23361621.
        View in: PubMed
      227. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40. PMID: 23358976.
        View in: PubMed
      228. Jain RK, Lee JJ, Hong D, Kurzrock R. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396. PMID: 23451354.
        View in: PubMed
      229. Janku F, Munoz J, Subbiah V, Kurzrock R. A tale of two histiocytic disorders. Oncologist. 2013; 18(1):2-4. PMID: 23299771.
        View in: PubMed
      230. Cohen PR, Kurzrock R, Parish LC. Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. Clin Dermatol. 2013 Jan-Feb; 31(1):128-30. PMID: 23245984.
        View in: PubMed
      231. Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013; 33:127-34. PMID: 23714478.
        View in: PubMed
      232. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217.
        View in: PubMed
      233. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555.
        View in: PubMed
      234. Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorg Med Chem. 2013 Feb 15; 21(4):932-9. PMID: 23294827.
        View in: PubMed
      235. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
        View in: PubMed
      236. Westin JR, Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012 Dec; 11(12):2549-55. PMID: 23204432.
        View in: PubMed
      237. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87. PMID: 23199899.
        View in: PubMed
      238. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. PMID: 23179336.
        View in: PubMed
      239. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
        View in: PubMed
      240. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256.
        View in: PubMed
      241. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 1; 73(1):276-84. PMID: 23066039.
        View in: PubMed
      242. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63. PMID: 23014530.
        View in: PubMed
      243. Munoz J, Kurzrock R. Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol. 2012 Nov; 9(11):631-42. PMID: 22965154.
        View in: PubMed
      244. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
        View in: PubMed
      245. Cohen PR, Prieto VG, Piha-Paul SA, Kurzrock R. The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. J Clin Aesthet Dermatol. 2012 Sep; 5(9):27-36. PMID: 23050032.
        View in: PubMed
      246. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012 Sep 25; 107(7):1093-9. PMID: 22935583.
        View in: PubMed
      247. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
        View in: PubMed
      248. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012 Nov; 11(11):2483-94. PMID: 22914438.
        View in: PubMed
      249. Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther. 2012 Nov; 11(11):2541-6. PMID: 22914439.
        View in: PubMed
      250. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81. PMID: 22805291.
        View in: PubMed
      251. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. PMID: 22805292.
        View in: PubMed
      252. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
        View in: PubMed
      253. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr. 2012 Jul-Aug; 36(4):388-93. PMID: 22805665.
        View in: PubMed
      254. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-3. PMID: 22745218.
        View in: PubMed
      255. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 1; 18(15):4173-82. PMID: 22693357.
        View in: PubMed
      256. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. PMID: 22689801.
        View in: PubMed
      257. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51. PMID: 22674635.
        View in: PubMed
      258. Paul LJ, Cohen PR, Kurzrock R. Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. Int J Dermatol. 2012 Jun; 51(6):631-46; quiz 643-4, 646. PMID: 22607279.
        View in: PubMed
      259. Subbiah V, Kurzrock R. Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012 Jun; 13(73):405-15. PMID: 22742646.
        View in: PubMed
      260. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
        View in: PubMed
      261. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430.
        View in: PubMed
      262. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
        View in: PubMed
      263. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012 May 19; 379(9829):1893-901. PMID: 22608338.
        View in: PubMed
      264. Munoz J, Naing A, Qi M, Kurzrock R. Cutaneous Castleman disease. Br J Haematol. 2012 Jun; 157(6):652. PMID: 22533925.
        View in: PubMed
      265. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
        View in: PubMed
      266. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1; 30(19):2348-53. PMID: 22529266.
        View in: PubMed
      267. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
        View in: PubMed
      268. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012 Jun; 11(6):1221-5. PMID: 22491798.
        View in: PubMed
      269. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 1; 18(9):2625-31. PMID: 22465830.
        View in: PubMed
      270. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943.
        View in: PubMed
      271. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-7. PMID: 22377564.
        View in: PubMed
      272. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35. PMID: 22355009.
        View in: PubMed
      273. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473.
        View in: PubMed
      274. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. PMID: 22229660.
        View in: PubMed
      275. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012; 7(1):e29330. PMID: 22235285.
        View in: PubMed
      276. Westin JR, Kantarjian H, Kurzrock R. Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. Am Soc Clin Oncol Educ Book. 2012; 179-85. PMID: 24451731.
        View in: PubMed
      277. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. PMID: 22205203.
        View in: PubMed
      278. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012 Feb; 11(2):308-16. PMID: 22203732.
        View in: PubMed
      279. Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8. PMID: 22203760.
        View in: PubMed
      280. Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95(1):1-2. PMID: 22170230.
        View in: PubMed
      281. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. PMID: 22039425.
        View in: PubMed
      282. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One. 2011; 6(10):e26060. PMID: 22022506.
        View in: PubMed
      283. Barosh BA, Holmes C, Keerikattu LM, Manappurathu MS, Segovia JH, Hasen PC, Pai SV, Lobiondo-Wood G, Kurzrock R. Advancing the scope of nursing practice: hepatic arterial catheter removal. Clin J Oncol Nurs. 2011 Oct; 15(5):465-8. PMID: 21951733.
        View in: PubMed
      284. Sedrak P, Ketonen L, Hou P, Guha-Thakurta N, Williams MD, Kurzrock R, Debnam JM. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol. 2011 Dec; 32(11):2126-31. PMID: 21960492.
        View in: PubMed
      285. Subbiah V, Angelo LS, Kurzrock R. Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opin Investig Drugs. 2011 Nov; 20(11):1471-7. PMID: 21936711.
        View in: PubMed
      286. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther. 2011 Nov; 10(11):2094-103. PMID: 21903608.
        View in: PubMed
      287. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 1; 17(21):6840-6. PMID: 21890452.
        View in: PubMed
      288. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1601-12. PMID: 21849857.
        View in: PubMed
      289. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821.
        View in: PubMed
      290. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. PMID: 21844494.
        View in: PubMed
      291. Piha-Paul SA, Cohen PR, Kurzrock R. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011 Sep 10; 29(26):e727-30. PMID: 21844496.
        View in: PubMed
      292. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. PMID: 21831956.
        View in: PubMed
      293. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 1; 118(5):1422-8. PMID: 21823111.
        View in: PubMed
      294. Garrido-Laguna I, Hidalgo M, Kurzrock R. The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol. 2011 Sep; 8(9):562-6. PMID: 21808269.
        View in: PubMed
      295. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508.
        View in: PubMed
      296. Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, Charnsangavej C. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology. 2011 Sep; 260(3):762-70. PMID: 21788525.
        View in: PubMed
      297. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. PMID: 21750201.
        View in: PubMed
      298. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Charnsangavej C, Kurzrock R. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol. 2011 Jul; 197(1):113-21. PMID: 21701018.
        View in: PubMed
      299. Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011 Jul; 23(4):352-60. PMID: 21519259.
        View in: PubMed
      300. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250. PMID: 21731684.
        View in: PubMed
      301. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Jan; 69(1):165-72. PMID: 21638123.
        View in: PubMed
      302. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1; 29(19):2660-6. PMID: 21606412.
        View in: PubMed
      303. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 Sep; 8(9):528-39. PMID: 21587219.
        View in: PubMed
      304. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7. PMID: 21571911.
        View in: PubMed
      305. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. PMID: 21538342.
        View in: PubMed
      306. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1507-16. PMID: 21499896.
        View in: PubMed
      307. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 1; 29(19):e572-5. PMID: 21482991.
        View in: PubMed
      308. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011; 6(4):e18424. PMID: 21494688.
        View in: PubMed
      309. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011; 16(4):497-511. PMID: 21441298.
        View in: PubMed
      310. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. PMID: 21415223.
        View in: PubMed
      311. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. PMID: 21339262.
        View in: PubMed
      312. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011; 2:81-9. PMID: 21326629.
        View in: PubMed
      313. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252.
        View in: PubMed
      314. Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011 Feb 1; 12(1):63-7. PMID: 20726623.
        View in: PubMed
      315. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 2011 Apr 20; 29(12):e333-5. PMID: 21263090.
        View in: PubMed
      316. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. PMID: 21216929.
        View in: PubMed
      317. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011 Jan; 10(1):209-17. PMID: 21220503.
        View in: PubMed
      318. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010 Dec; 9(12):3410-9. PMID: 21159616.
        View in: PubMed
      319. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4. PMID: 21208846.
        View in: PubMed
      320. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs. 2010 Dec; 19(12):1569-80. PMID: 21083522.
        View in: PubMed
      321. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
        View in: PubMed
      322. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010 Dec; 9(12):3254-66. PMID: 21041383.
        View in: PubMed
      323. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010 Oct 15; 116(20):4670-6. PMID: 20597137.
        View in: PubMed
      324. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1; 16(23):5883-91. PMID: 20947515.
        View in: PubMed
      325. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. PMID: 20941597.
        View in: PubMed
      326. Hui D, Parsons H, Nguyen L, Palla SL, Yennurajalingam S, Kurzrock R, Bruera E. Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. Cancer. 2010 Sep 15; 116(18):4402-9. PMID: 20564164.
        View in: PubMed
      327. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2012 Feb; 30(1):327-34. PMID: 20842406.
        View in: PubMed
      328. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 1; 116(17):4086-94. PMID: 20564148.
        View in: PubMed
      329. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 1; 117(1):77-85. PMID: 20737567.
        View in: PubMed
      330. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010 Nov 1; 28(31):e633-6. PMID: 20733125.
        View in: PubMed
      331. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug 10; 28(23):3701-8. PMID: 20625121.
        View in: PubMed
      332. Subbiah V, Trent JC, Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415. PMID: 20567010.
        View in: PubMed
      333. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol. 2010 Jul; 7(7):401-14. PMID: 20551945.
        View in: PubMed
      334. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 1; 16(15):4031-7. PMID: 20525754.
        View in: PubMed
      335. Bustinza-Linares E, Kurzrock R, Tsimberidou AM. Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010 Jun; 6(6):885-91. PMID: 20528225.
        View in: PubMed
      336. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther. 2010 Jun; 9(6):1485-8. PMID: 20501803.
        View in: PubMed
      337. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010 Jun 10; 28(17):2839-46. PMID: 20458040.
        View in: PubMed
      338. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010 Jun 10; 28(17):2925-35. PMID: 20406924.
        View in: PubMed
      339. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010 Apr 15; 16(8):2458-65. PMID: 20371689.
        View in: PubMed
      340. Naing A, Kurzrock R. Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer. 2010 Apr; 9(2):E1-4. PMID: 20378496.
        View in: PubMed
      341. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123.
        View in: PubMed
      342. Chintala L, Kurzrock R. Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review. Mol Oncol. 2010 Aug; 4(4):306-8. PMID: 20346742.
        View in: PubMed
      343. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93. PMID: 20204368.
        View in: PubMed
      344. Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA. Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res. 2010 Mar; 30(3):811-4. PMID: 20393001.
        View in: PubMed
      345. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res. 2010 Feb 15; 16(4):1256-63. PMID: 20145186.
        View in: PubMed
      346. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97. PMID: 20145187.
        View in: PubMed
      347. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010; 15(2):130-41. PMID: 20139170.
        View in: PubMed
      348. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol. 2010 Feb; 194(2):W134-40. PMID: 20093564.
        View in: PubMed
      349. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
        View in: PubMed
      350. Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist. 2010; 15(1):37-50. PMID: 20080862.
        View in: PubMed
      351. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41. PMID: 19484470.
        View in: PubMed
      352. Naing A, Aaron J, Kurzrock R. Juice plus or toxicity plus. Am J Med. 2010 Jan; 123(1):e1-2. PMID: 20102976.
        View in: PubMed
      353. Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R. Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biol Ther. 2009 Dec; 8(23):2239-47. PMID: 19823028.
        View in: PubMed
      354. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009 Dec; 38(6):894-902. PMID: 19692203.
        View in: PubMed
      355. Davis R, Singh KP, Kurzrock R, Shankar S. Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep. 2009 Dec; 22(6):1473-8. PMID: 19885601.
        View in: PubMed
      356. Janku F, Kurzrock R. Adjuvant interferon in high-risk melanoma: end of the era? J Clin Oncol. 2010 Jan 10; 28(2):e15-6; author reply e17-8. PMID: 19949007.
        View in: PubMed
      357. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009 Nov 15; 115(22):5309-18. PMID: 19701908.
        View in: PubMed
      358. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778.
        View in: PubMed
      359. Angelo LS, Kurzrock R. Target validation using Phase 0 clinical trials: Promises and pitfalls. Cancer Biol Ther. 2009 Nov; 8(21):2010-2. PMID: 20037466.
        View in: PubMed
      360. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol. 2009 Dec 20; 27(36):6243-50. PMID: 19826112.
        View in: PubMed
      361. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016.
        View in: PubMed
      362. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC. Project Zero Delay: a process for accelerating the activation of cancer clinical trials. J Clin Oncol. 2009 Sep 10; 27(26):4433-40. PMID: 19652061.
        View in: PubMed
      363. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res. 2009 Jul 15; 15(14):4769-76. PMID: 19584162.
        View in: PubMed
      364. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol. 2009 Jul; 84(7):408-13. PMID: 19437507.
        View in: PubMed
      365. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009 Jul 20; 27(21):3557-65. PMID: 19546406.
        View in: PubMed
      366. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther. 2009 Jun; 8(6):1596-605. PMID: 19509267.
        View in: PubMed
      367. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct; 28(5):634-40. PMID: 19499186.
        View in: PubMed
      368. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009 Jun; 29(6):1895-9. PMID: 19528445.
        View in: PubMed
      369. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 1; 15(11):3881-8. PMID: 19470736.
        View in: PubMed
      370. Braiteh F, Kurzrock R. Electronic clinical challenges and images in GI. Image 2. Extensive bilateral extracranial subcutaneous fluid collection. Gastroenterology. 2009 Jun; 136(7):e3-6. PMID: 19427926.
        View in: PubMed
      371. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer. 2009 Apr 15; 115(8):1592-7. PMID: 19165808.
        View in: PubMed
      372. Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R. Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. Mol Cancer Ther. 2009 Mar; 8(3):703-10. PMID: 19258427.
        View in: PubMed
      373. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009 Mar 1; 115(5):1091-9. PMID: 19165805.
        View in: PubMed
      374. Angelo LS, Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin Cancer Res. 2009 Feb 15; 15(4):1123-5. PMID: 19228716.
        View in: PubMed
      375. Freireich EJ, Kurzrock R. The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol. 2009 Jan 10; 27(2):304-6. PMID: 19064962.
        View in: PubMed
      376. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009 Jan 20; 27(3):328-33. PMID: 19064964.
        View in: PubMed
      377. Sun G, Berthelot C, Li Y, Glass DA, George D, Pandya A, Kurzrock R, Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009 Feb; 60(2):231-5. PMID: 19026464.
        View in: PubMed
      378. Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, Shete S, Bruera E. The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3262-7. PMID: 18990769.
        View in: PubMed
      379. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008 Oct 1; 14(19):6296-301. PMID: 18829512.
        View in: PubMed
      380. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008 Oct 1; 113(7):1605-13. PMID: 18683214.
        View in: PubMed
      381. Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008 Sep; 7(9):2575-88. PMID: 18790742.
        View in: PubMed
      382. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol. 2008 Aug; 9(8):777-85. PMID: 18672213.
        View in: PubMed
      383. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15; 14(14):4491-9. PMID: 18628464.
        View in: PubMed
      384. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008 Jul 10; 26(20):3460-2. PMID: 18612164.
        View in: PubMed
      385. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008 Jun; 144(6):779-82. PMID: 18559769.
        View in: PubMed
      386. Naing A, Reuben JM, Verschraegen CF, Camacho LH, Stephen S, Hong DS, Wheler JJ, Fu S, Martinez M, Akinsanmi L, Kurzrock R. Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3011. PMID: 27947630.
        View in: PubMed
      387. Stewart DJ, Nunez M, Jelinek J, Guo Z, Hong DS, Wistuba II, Issa JP, Kurzrock R. Tumor CTR1 copper transporter modulation by decitabine (DAC) and relationship to global DNA methylation and time from prior therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):11088. PMID: 27947704.
        View in: PubMed
      388. Wheler JJ, Tsimberidou AM, Hong DS, Jackson TL, Polk DY, Pilat S, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: The M. D. Anderson Cancer Center experience. J Clin Oncol. 2008 May 20; 26(15_suppl):11066. PMID: 27947723.
        View in: PubMed
      389. Infante JR, Spratlin JL, Kurzrock R, Eckhardt SG, Burris HA, Puchalski TA, Li J, Wu K, Ochs J, Herbst RS. Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):2501. PMID: 27947750.
        View in: PubMed
      390. Fu S, Chintala L, Madoff D, Hong DS, Naing A, Moulder SL, Wheler JJ, Ng CS, Lim J, Patterson M, Kurzrock R. A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluorouracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases. J Clin Oncol. 2008 May 20; 26(15_suppl):2534. PMID: 27947773.
        View in: PubMed
      391. Reyes-Gibby CC, El Osta BE, Spitz M, Parsons HA, Kurzrock R, Shete S, Bruera E. The influence of polymorphisms in cytokine genes on pain and response to analgesia in lung cancer patients receiving palliative treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):9503. PMID: 27948183.
        View in: PubMed
      392. Braiteh F, Dalal S, Khuwaja A, David H, Bruera E, Kurzrock R. Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):20529. PMID: 27949338.
        View in: PubMed
      393. Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). J Clin Oncol. 2008 May 20; 26(15_suppl):3593. PMID: 27949369.
        View in: PubMed
      394. Camacho LH, Moulder SL, LoRusso PM, Blumenschein GR, Bristow PJ, Kurzrock R, Fu S, Schlienger K, Bergstrom DA. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14657. PMID: 27949497.
        View in: PubMed
      395. Moulder SL, Dhillon N, Hong DS, Ng CS, Camacho LH, Hersh EM, Grenier KA, Boytim ML, Dorr RT, Kurzrock R. A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):3589. PMID: 27949687.
        View in: PubMed
      396. Aghajanian CA, Hamlin P, Gordon MS, Hong DS, Naing A, Younes A, Hannah A, Palladino MA, Spear MA, Kurzrock R. Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3574. PMID: 27949708.
        View in: PubMed
      397. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol. 2008 May 20; 26(15_suppl):3522. PMID: 27949731.
        View in: PubMed
      398. Tsimberidou AM, Rudek MA, Hong DS, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase I first-in-human study of s-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3536. PMID: 27949793.
        View in: PubMed
      399. Nemunaitis JJ, Senzer NN, Kurzrock R, Ng CS, Das A, Atienza RS, Zang EA, Jansen M, Ashworth S, Hong DS. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14583. PMID: 27950116.
        View in: PubMed
      400. Falchook GS, Jackson EF, Wheler JJ, Moulder SL, Hong DS, Naing A, Tannir NM, Lawhorn KN, Ng CS, Kurzrock R. Anti-angiogenic therapy in combination with hypoxia-inducible factor-1a (HIF-1a) modulation. J Clin Oncol. 2008 May 20; 26(15_suppl):14604. PMID: 27950161.
        View in: PubMed
      401. Vemulapalli S, Kurzrock R, Fritsche H, Wheler JJ, Moulder SL, Cristofanilli M, Gonzalez-De Luna M, Khan R, Xu Y, Hong DS. Phase I open-labeled trial of gemcitabine and dasatinib in advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14626. PMID: 27950257.
        View in: PubMed
      402. Guo Z, Wheler JJ, Naing A, Mani S, Goel S, Mulcahy M, Gamza F, Longley C, Buchbinder A, Kurzrock R. Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study. J Clin Oncol. 2008 May 20; 26(15_suppl):2556. PMID: 27947917.
        View in: PubMed
      403. Takimoto CH, Fu S, Dhillon N, Mita MM, Mita AC, Cheung W, Xu Y, Ali A, Johri A, Kurzrock R. Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):2548. PMID: 27947937.
        View in: PubMed
      404. Hong DS, Kurzrock R, Supko JG, Lawrence DP, Wheler JJ, Meyer CJ, Mier JW, Andreeff M, Shapiro GI, Dezube BJ. Phase I trial with a novel oral NF-?B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):3517. PMID: 27949759.
        View in: PubMed
      405. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6. PMID: 18445656.
        View in: PubMed
      406. Cen P, Duvic M, Cohen PR, Kurzrock R. Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. J Am Acad Dermatol. 2008 Mar; 58(3):382-6. PMID: 18280334.
        View in: PubMed
      407. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008 Mar; 7(3):464-73. PMID: 18347134.
        View in: PubMed
      408. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14. PMID: 18223226.
        View in: PubMed
      409. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
        View in: PubMed
      410. Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, Bruera E, Kurzrock R, Shete S. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev. 2007 Dec; 16(12):2745-51. PMID: 18086782.
        View in: PubMed
      411. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007 Nov 1; 110(9):1911-28. PMID: 17849470.
        View in: PubMed
      412. Lyu MA, Kurzrock R, Rosenblum MG. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. Biochem Pharmacol. 2008 Feb 15; 75(4):836-46. PMID: 18082672.
        View in: PubMed
      413. Kurzrock R. Studies in target-based treatment. Mol Cancer Ther. 2007 Sep; 6(9):2385. PMID: 17846118.
        View in: PubMed
      414. Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R. Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther. 2007 Sep; 6(9):2386-90. PMID: 17766835.
        View in: PubMed
      415. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007 Jun 10; 25(17):2369-76. PMID: 17557949.
        View in: PubMed
      416. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007 Jun 1; 109(11):2190-6. PMID: 17464952.
        View in: PubMed
      417. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007 May 15; 13(10):2825-30. PMID: 17504979.
        View in: PubMed
      418. Kurzrock R. Studies in target-based treatment. Mol Cancer Ther. 2007 May; 6(5):1477. PMID: 17483434.
        View in: PubMed
      419. Kurzrock R. I have good news! You have leukemia. Clin Dermatol. 2007 May-Jun; 25(3):350-2. PMID: 17560314.
        View in: PubMed
      420. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007 May-Jun; 25(3):326-33. PMID: 17560310.
        View in: PubMed
      421. Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. Improving the institutional submission and approval process for clinical research protocols in oncology. J Clin Oncol. 2007 Apr 20; 25(12):1632-3. PMID: 17443009.
        View in: PubMed
      422. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 2007 Apr; 6(4):1276-82. PMID: 17431105.
        View in: PubMed
      423. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther. 2007 Apr; 6(4):1175-9. PMID: 17431100.
        View in: PubMed
      424. Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007 May 15; 109(10):4158-63. PMID: 17264294.
        View in: PubMed
      425. Braiteh F, Cohen PR, Kurzrock R. CAT scan reveals BAT sign. Lancet. 2007 Jan 20; 369(9557):217. PMID: 17240288.
        View in: PubMed
      426. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther. 2006 Dec; 5(12):2991-3000. PMID: 17148761.
        View in: PubMed
      427. Kurzrock R, Cohen PR. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. Med Hypotheses. 2007; 68(3):480-3. PMID: 17134841.
        View in: PubMed
      428. Braiteh F, Lim JT, Kurzrock R. Computed axial tomography scanning (CT scan). Clin Anat. 2006 Oct; 19(7):682-3. PMID: 16964604.
        View in: PubMed
      429. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006 Oct; 47(10):2049-54. PMID: 17071475.
        View in: PubMed
      430. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther. 2006 Sep; 5(9):2251-60. PMID: 16985059.
        View in: PubMed
      431. Kurzrock R, Talpaz M, Li L, Estrov Z. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leuk Lymphoma. 2006 Aug; 47(8):1651-64. PMID: 16966279.
        View in: PubMed
      432. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006 Jul; 7(1):51-8. PMID: 16879770.
        View in: PubMed
      433. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006 May; 47(5):827-36. PMID: 16753866.
        View in: PubMed
      434. Kurzrock R, Ravandi F. Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S27-34. PMID: 16549112.
        View in: PubMed
      435. Braiteh F, Ng C, Kurzrock R. Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin). Leuk Lymphoma. 2006 Feb; 47(2):373-5. PMID: 16321875.
        View in: PubMed
      436. Braiteh F, Kurzrock R. CASE 1. Langerhans cell histiocytosis of the thyroid. J Clin Oncol. 2006 Jan 20; 24(3):522-3. PMID: 16421429.
        View in: PubMed
      437. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005 Sep 15; 104(6):1322-31. PMID: 16092118.
        View in: PubMed
      438. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. 2005 Aug 15; 104(4):879-90. PMID: 16007726.
        View in: PubMed
      439. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005 Nov 1; 106(9):2992-4. PMID: 16020507.
        View in: PubMed
      440. Kurzrock R, Li L. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. J Clin Oncol. 2005 Jun; 23(16_suppl):4091. PMID: 27944221.
        View in: PubMed
      441. Stewart DJ, Kurzrock R, Oki Y, Kehr K, Gupta S, Wistuba II, Camacho LH, Issa JP. Pharmacodynamics of decitabine 5 days/week x 2 weeks in advanced cancers. J Clin Oncol. 2005 Jun; 23(16_suppl):3110. PMID: 27946096.
        View in: PubMed
      442. Freireich EJ, Kurzrock R, Estrov Z. Metastasis--an alternative hypothesis. Cancer. 2005 Apr 15; 103(8):1537-9. PMID: 15739196.
        View in: PubMed
      443. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med. 2005 Mar 3; 352(9):930-2. PMID: 15745986.
        View in: PubMed
      444. Kurzrock R. Farnesyltransferase inhibitors. Clin Adv Hematol Oncol. 2005 Mar; 3(3):161-2. PMID: 16166986.
        View in: PubMed
      445. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005 Apr 20; 23(12):2805-12. PMID: 15728224.
        View in: PubMed
      446. Kurzrock R. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. Clin Cancer Res. 2005 Feb 15; 11(4):1361-7. PMID: 15746033.
        View in: PubMed
      447. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol. 2005; 45:357-84. PMID: 15822181.
        View in: PubMed
      448. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005 Jan; 16(1):139-45. PMID: 15598951.
        View in: PubMed
      449. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004 Dec 15; 101(12):2727-36. PMID: 15526319.
        View in: PubMed
      450. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 2004 Nov 15; 101(10):2351-62. PMID: 15476283.
        View in: PubMed
      451. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol. 2004 Aug; 51(2):200-4. PMID: 15280837.
        View in: PubMed
      452. Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev. 2004 Aug; 30(5):425-36. PMID: 15245775.
        View in: PubMed
      453. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004 Aug 1; 104(3):655-8. PMID: 15073032.
        View in: PubMed
      454. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 1; 22(7):1287-92. PMID: 15051776.
        View in: PubMed
      455. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004 Feb 1; 100(3):574-80. PMID: 14745875.
        View in: PubMed
      456. Cohen PR, Kurzrock R. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol. 2004 Feb; 50(2):277-80. PMID: 14726887.
        View in: PubMed
      457. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004 Feb 1; 10(3):803-21. PMID: 14871955.
        View in: PubMed
      458. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004 Jan 15; 100(2):342-9. PMID: 14716770.
        View in: PubMed
      459. Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer. 2003 Dec 1; 98(11):2410-9. PMID: 14635076.
        View in: PubMed
      460. Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov; 17(11):2196-201. PMID: 14523478.
        View in: PubMed
      461. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003 Nov; 17(11):2101-6. PMID: 12931212.
        View in: PubMed
      462. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol. 2003 Oct; 42(10):761-78. PMID: 14521689.
        View in: PubMed
      463. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M, Kurzrock R. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1):3722-30. PMID: 14506164.
        View in: PubMed
      464. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34. PMID: 12947010.
        View in: PubMed
      465. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8. PMID: 12910522.
        View in: PubMed
      466. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003 Jul; 49(1):35-49. PMID: 12833006.
        View in: PubMed
      467. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003 May 20; 138(10):819-30. PMID: 12755554.
        View in: PubMed
      468. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003 Mar 1; 101(5):1692-7. PMID: 12411300.
        View in: PubMed
      469. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002 Oct; 39(4 Suppl 3):20-4. PMID: 12447848.
        View in: PubMed
      470. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15; 100(4):1215-9. PMID: 12149200.
        View in: PubMed
      471. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002 Sep; 50(3):237-42. PMID: 12203106.
        View in: PubMed
      472. Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, Wang JY, Talpaz M. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer. 2002 Jul 15; 95(2):440-50. PMID: 12124845.
        View in: PubMed
      473. Kurzrock R. Myelodysplastic syndrome overview. Semin Hematol. 2002 Jul; 39(3 Suppl 2):18-25. PMID: 12214289.
        View in: PubMed
      474. Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):36-8. PMID: 12214292.
        View in: PubMed
      475. Cortes JE, Kurzrock R, Kantarjian HM. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30. PMID: 12214290.
        View in: PubMed
      476. Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 2002 Feb 1; 62(3):932-40. PMID: 11830554.
        View in: PubMed
      477. Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol. 2002; 3(2):117-31. PMID: 11893223.
        View in: PubMed
      478. Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001 Dec; 132(6):945-7. PMID: 11730673.
        View in: PubMed
      479. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother. 2001 Nov; 55(9-10):543-7. PMID: 11769963.
        View in: PubMed
      480. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001 Nov 1; 19(21):4165-72. PMID: 11689585.
        View in: PubMed
      481. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001 Sep 15; 92(6 Suppl):1684-8. PMID: 11598887.
        View in: PubMed
      482. Kurzrock R. Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci. 2001 Sep; 941:200-5. PMID: 11594574.
        View in: PubMed
      483. Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001 Jun 1; 19(11):2915-26. PMID: 11387365.
        View in: PubMed
      484. Kurzrock R, Kantarjian H, Talpaz M. Chronic myelogenous leukemia in chronic phase. Curr Treat Options Oncol. 2001 Jun; 2(3):245-52. PMID: 12057124.
        View in: PubMed
      485. Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood. 2001 May 1; 97(9):2791-7. PMID: 11313273.
        View in: PubMed
      486. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001 Mar 15; 61(6):2343-55. PMID: 11289094.
        View in: PubMed
      487. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 1; 97(1):256-63. PMID: 11133769.
        View in: PubMed
      488. Laurent E, Talpaz M, Wetzler M, Kurzrock R. Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins. Leukemia. 2000 Nov; 14(11):1892-7. PMID: 11069024.
        View in: PubMed
      489. Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. Oncology (Williston Park). 2000 Sep; 14(9 Suppl 8):9-11. PMID: 11033833.
        View in: PubMed
      490. Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R. Autoantibodies to Abl and Bcr proteins. Leukemia. 2000 Sep; 14(9):1661-6. PMID: 10995014.
        View in: PubMed
      491. Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000 May-Jun; 18(3):265-82. PMID: 10856659.
        View in: PubMed
      492. Kurzrock R. Pentostatin (Nipent) in T-cell lymphomas. Semin Oncol. 2000 Apr; 27(2 Suppl 5):64-6. PMID: 10877055.
        View in: PubMed
      493. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000; 6(1):25-34. PMID: 10707996.
        View in: PubMed
      494. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8. PMID: 10632330.
        View in: PubMed
      495. Giles FJ, Keating AR, Kurzrock R, Talpaz M. A pilot study of recombinant human interleukin-4 therapy of myelofibrosis. J Interferon Cytokine Res. 1999 Nov; 19(11):1253-5. PMID: 10574617.
        View in: PubMed
      496. Faderl S, Kurzrock R, Estrov Z. Minimal residual disease in hematologic disorders. Arch Pathol Lab Med. 1999 Nov; 123(11):1030-4. PMID: 10539902.
        View in: PubMed
      497. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999 Oct; 17(10):3117-21. PMID: 10506607.
        View in: PubMed
      498. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72. PMID: 10403855.
        View in: PubMed
      499. Beaupre DM, Talpaz M, Marini FC, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999 Jun 15; 59(12):2971-80. PMID: 10383163.
        View in: PubMed
      500. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 1999 Jun; 40(6 Pt 1):914-24. PMID: 10365922.
        View in: PubMed
      501. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999 Mar; 17(3):1071-9. PMID: 10071302.
        View in: PubMed
      502. Cohen PR, Kurzrock R. 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. Am J Dermatopathol. 1999 Feb; 21(1):106-8. PMID: 10027536.
        View in: PubMed
      503. Beaupre DM, Kurzrock R. RAS inhibitors in hematologic cancers: biologic considerations and clinical applications. Invest New Drugs. 1999; 17(2):137-43. PMID: 10638484.
        View in: PubMed
      504. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998 Aug 15; 92(4):1150-9. PMID: 9694702.
        View in: PubMed
      505. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma. 1998 Aug; 30(5-6):563-71. PMID: 9711918.
        View in: PubMed
      506. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma. 1998 Jul; 30(3-4):279-92. PMID: 9713960.
        View in: PubMed
      507. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia. 1998 Jun; 12(6):860-4. PMID: 9639411.
        View in: PubMed
      508. Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998 Apr; 22(4):341-53. PMID: 9669839.
        View in: PubMed
      509. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31. PMID: 9552062.
        View in: PubMed
      510. Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M. Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med. 1998 Mar; 131(3):261-8. PMID: 9523851.
        View in: PubMed
      511. Kurzrock R, Talpaz M, Beran M, Harris D, Estrov Z. DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia. 1998 Feb; 12(2):242-6. PMID: 9519789.
        View in: PubMed
      512. Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ. Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2723-33. PMID: 10068280.
        View in: PubMed
      513. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2581-4. PMID: 9815659.
        View in: PubMed
      514. Cohen PR, Kurzrock R. Transient acantholytic dermatosis after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 1997 Sep; 77(5):412-3. PMID: 9298152.
        View in: PubMed
      515. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med. 1997 Aug 1; 127(3):186-94. PMID: 9245223.
        View in: PubMed
      516. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jul; 26(3-4):251-9. PMID: 9322887.
        View in: PubMed
      517. Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz M. Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leuk Res. 1997 Jun; 21(6):519-27. PMID: 9279363.
        View in: PubMed
      518. Cohen PR, Kurzrock R. Mucocutaneous paraneoplastic syndromes. Semin Oncol. 1997 Jun; 24(3):334-59. PMID: 9208889.
        View in: PubMed
      519. Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):291-305. PMID: 9376665.
        View in: PubMed
      520. Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997 May; 15(5):1803-10. PMID: 9164188.
        View in: PubMed
      521. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma. 1997 Mar; 25(1-2):121-33. PMID: 9130620.
        View in: PubMed
      522. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997 Feb; 96(2):328-32. PMID: 9029021.
        View in: PubMed
      523. Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia. 1997 Jan; 11(1):42-7. PMID: 9001417.
        View in: PubMed
      524. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med. 1997 Jan; 102(1):21-8. PMID: 9209197.
        View in: PubMed
      525. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996 Oct 1; 88(7):2385-409. PMID: 8839829.
        View in: PubMed
      526. Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia. 1996 Sep; 10(9):1534-43. PMID: 8751477.
        View in: PubMed
      527. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996 Jun; 34(6):1022-9. PMID: 8647968.
        View in: PubMed
      528. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer. 1996 May 16; 66(4):515-9. PMID: 8635867.
        View in: PubMed
      529. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 1; 87(9):3650-4. PMID: 8611689.
        View in: PubMed
      530. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30. PMID: 8600166.
        View in: PubMed
      531. Seymour JF, Kurzrock R. Interleukin-6: biologic properties and role in lymphoproliferative disorders. Cancer Treat Res. 1996; 84:167-206. PMID: 8724631.
        View in: PubMed
      532. Kurzrock R, Cohen PR. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med. 1995 Dec; 99(6):662-71. PMID: 7503090.
        View in: PubMed
      533. Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Ost A, Cork A, Trujillo JM, Freireich EJ, Siciliano MJ. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia. 1995 Dec; 9(12):2100-8. PMID: 8609723.
        View in: PubMed
      534. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med. 1995 Oct; 99(4):402-11. PMID: 7573097.
        View in: PubMed
      535. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res. 1995 Oct; 15(10):905-13. PMID: 8564713.
        View in: PubMed
      536. Kurzrock R, Wetzler M, Estrov Z, Talpaz M. Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther. 1995 Sep; 1(3):177-84. PMID: 9384674.
        View in: PubMed
      537. Wetzler M, Kurzrock R, Goodacre AM, McLaughlin P, Ku S, Talpaz M. Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer. 1995 Aug 15; 76(4):609-17. PMID: 8625154.
        View in: PubMed
      538. Kurzrock R, Cohen PR. Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am J Med. 1995 Aug; 99(2):207-16. PMID: 7625426.
        View in: PubMed
      539. Estrov Z, Kurzrock R, Talpaz M. Cytokines and their antagonists in myeloid disorders. Semin Hematol. 1995 Jul; 32(3):220-31. PMID: 7570065.
        View in: PubMed
      540. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995 Jun; 98(6):551-8. PMID: 7539977.
        View in: PubMed
      541. Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia. 1995 May; 9(5):929-32. PMID: 7769859.
        View in: PubMed
      542. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995 May 1; 85(9):2516-20. PMID: 7537119.
        View in: PubMed
      543. Wetzler M, Talpaz M, Yee G, Stass SA, Van Etten RA, Andreeff M, Goodacre AM, Kleine HD, Mahadevia RK, Kurzrock R. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3488-92. PMID: 7724587.
        View in: PubMed
      544. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995 Mar; 13(3):575-82. PMID: 7884418.
        View in: PubMed
      545. Kurzrock R, Cohen PR. Erythema gyratum repens. JAMA. 1995 Feb 15; 273(7):594. PMID: 7837395.
        View in: PubMed
      546. Kurzrock R, Cohen PR. Classification and diagnosis of erythromelalgia. Int J Dermatol. 1995 Feb; 34(2):146-7. PMID: 7794397.
        View in: PubMed
      547. Kurzrock R, Ku S, Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer. 1995 Jan 15; 75(2):584-90. PMID: 7812927.
        View in: PubMed
      548. Estrov Z, Kurzrock R, Talpaz M. Interleukin-1 and its inhibitors: implications for disease biology and therapy. Cancer Treat Res. 1995; 80:51-82. PMID: 8821574.
        View in: PubMed
      549. Cohen PR, Kohn SR, Davis DA, Kurzrock R. Muir-Torre syndrome. Dermatol Clin. 1995 Jan; 13(1):79-89. PMID: 7712655.
        View in: PubMed
      550. Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res. 1995 Jan; 19(1):23-34. PMID: 7837815.
        View in: PubMed
      551. Cohen PR, Kurzrock R. Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. Dermatol Clin. 1995 Jan; 13(1):211-29. PMID: 7712645.
        View in: PubMed
      552. Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z. Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells. 1994 Nov; 12(6):638-49. PMID: 7533582.
        View in: PubMed
      553. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 1; 84(9):3142-7. PMID: 7949186.
        View in: PubMed
      554. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9. PMID: 7929813.
        View in: PubMed
      555. Stoter G, Arnold AA, Kurzrock R, Rustin GJ. Financial concerns prompt sponsoring pharmaceutical company to halt international phase I studies. J Natl Cancer Inst. 1994 Sep 7; 86(17):1353. PMID: 8064897.
        View in: PubMed
      556. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994 Aug 1; 84(3):733-8. PMID: 7913841.
        View in: PubMed
      557. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994 May 15; 83(10):2906-11. PMID: 7910051.
        View in: PubMed
      558. Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. Cancer Res. 1994 Apr 1; 54(7):1837-42. PMID: 8137298.
        View in: PubMed
      559. Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med. 1994 Feb 14; 154(3):334-40. PMID: 8297201.
        View in: PubMed
      560. Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R. What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? Am J Med. 1994 Feb; 96(2):133-8. PMID: 8109597.
        View in: PubMed
      561. Cohen PR, Holder WR, Tucker SB, Kono S, Kurzrock R. Sweet syndrome in patients with solid tumors. Cancer. 1993 Nov 1; 72(9):2723-31. PMID: 8402496.
        View in: PubMed
      562. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med. 1993 Oct; 234(4):417-20. PMID: 7691980.
        View in: PubMed
      563. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest. 1993 Oct; 92(4):1925-39. PMID: 8408645.
        View in: PubMed
      564. Cohen PR, Kurzrock R. Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. Ann Rheum Dis. 1993 Sep; 52(9):685-8. PMID: 8239765.
        View in: PubMed
      565. Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol. 1993 Aug; 11(8):1489-95. PMID: 8336187.
        View in: PubMed
      566. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1; 82(3):691-703. PMID: 8338938.
        View in: PubMed
      567. Estrov Z, Kurzrock R, Talpaz M. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk Lymphoma. 1993 Aug; 10(6):407-18. PMID: 8401177.
        View in: PubMed
      568. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993 Aug 1; 53(15):3603-10. PMID: 8339266.
        View in: PubMed
      569. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93. PMID: 8324740.
        View in: PubMed
      570. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993 May 1; 53(9):2118-22. PMID: 8481913.
        View in: PubMed
      571. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 1; 177(3):763-74. PMID: 8382256.
        View in: PubMed
      572. Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells. 1993 Mar; 11(2):112-9. PMID: 8384506.
        View in: PubMed
      573. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20. PMID: 8426475.
        View in: PubMed
      574. Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol. 1993 Jan-Mar; 11(1):149-57. PMID: 8339190.
        View in: PubMed
      575. Kurzrock R, Cohen PR. Paraneoplastic erythromelalgia. Clin Dermatol. 1993 Jan-Mar; 11(1):73-82. PMID: 8339204.
        View in: PubMed
      576. Kurzrock R, Cohen PR. Vasculitis and cancer. Clin Dermatol. 1993 Jan-Mar; 11(1):175-87. PMID: 8339194.
        View in: PubMed
      577. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk Lymphoma. 1993; 11 Suppl 1:47-50. PMID: 8251916.
        View in: PubMed
      578. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5. PMID: 8417962.
        View in: PubMed
      579. Cohen PR, Grossman ME, Silvers DN, Kurzrock R. Tripe palms and cancer. Clin Dermatol. 1993 Jan-Mar; 11(1):165-73. PMID: 8339193.
        View in: PubMed
      580. Estrov Z, Talpaz M, Wetzler M, Kurzrock R. The modulatory hematopoietic activities of leukemia inhibitory factor. Leuk Lymphoma. 1992 Sep; 8(1-2):1-7. PMID: 1493463.
        View in: PubMed
      581. Cohen PR, Kurzrock R. Malignancy-associated tripe palms. J Am Acad Dermatol. 1992 Aug; 27(2 Pt 1):271-2. PMID: 1430373.
        View in: PubMed
      582. Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU. The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. Exp Hematol. 1992 Aug; 20(7):886-90. PMID: 1628706.
        View in: PubMed
      583. Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia. 1992 Aug; 6(8):754-60. PMID: 1640725.
        View in: PubMed
      584. Cohen PR, Kurzrock R. Extracutaneous manifestations of Sweet's syndrome: steroid-responsive culture-negative pulmonary lesions. Am Rev Respir Dis. 1992 Jul; 146(1):269. PMID: 1626811.
        View in: PubMed
      585. Kurzrock R, Talpaz M, Gutterman JU. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med. 1992 Jul; 93(1):41-8. PMID: 1626572.
        View in: PubMed
      586. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol. 1992 Jun; 20(5):558-64. PMID: 1587302.
        View in: PubMed
      587. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992 Apr 15; 79(8):1938-45. PMID: 1373331.
        View in: PubMed
      588. Wetzler M, Talpaz M, Kellagher MJ, Gutterman JU, Kurzrock R. Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF. JAMA. 1992 Apr 22-29; 267(16):2179-80. PMID: 1556785.
        View in: PubMed
      589. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res. 1992 Mar 1; 52(5):1087-90. PMID: 1737366.
        View in: PubMed
      590. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992 Feb 15; 79(4):882-7. PMID: 1346577.
        View in: PubMed
      591. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer. 1992 Jan 15; 69(2):410-2. PMID: 1370212.
        View in: PubMed
      592. Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991 Dec; 63(6):297-301. PMID: 1756190.
        View in: PubMed
      593. Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer. 1991 Nov 15; 68(10):2125-30. PMID: 1913450.
        View in: PubMed
      594. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood. 1991 Nov 1; 78(9):2400-6. PMID: 1932751.
        View in: PubMed
      595. Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JU. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991 Nov; 5(11):985-90. PMID: 1961041.
        View in: PubMed
      596. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991 Nov 1; 78(9):2411-8. PMID: 1932753.
        View in: PubMed
      597. Kurzrock R, Talpaz M, Gutterman JU. Hairy cell leukaemia: review of treatment. Br J Haematol. 1991 Oct; 79 Suppl 1:17-20. PMID: 1718389.
        View in: PubMed
      598. Kurzrock R, Talpaz M. The molecular pathology of chronic myelogenous leukaemia. Br J Haematol. 1991 Oct; 79 Suppl 1:34-7. PMID: 1931706.
        View in: PubMed
      599. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Interferon alpha in the therapy of CML. Br J Haematol. 1991 Oct; 79 Suppl 1:38-41. PMID: 1931707.
        View in: PubMed
      600. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 1991 Oct 1; 68(7):1536-7. PMID: 1893353.
        View in: PubMed
      601. Kurzrock R, Cohen PR. Erythromelalgia: review of clinical characteristics and pathophysiology. Am J Med. 1991 Oct; 91(4):416-22. PMID: 1951386.
        View in: PubMed
      602. Cohen PR, Kurzrock R. The pathogenesis of Sweet's syndrome. J Am Acad Dermatol. 1991 Oct; 25(4):734. PMID: 1724249.
        View in: PubMed
      603. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84. PMID: 1715791.
        View in: PubMed
      604. Kurzrock R, Talpaz M, Gutterman JU. Treatment of cyclic neutropenia with very low doses of GM-CSF. Am J Med. 1991 Sep; 91(3):317-8. PMID: 1892155.
        View in: PubMed
      605. Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz M. LIF: not just a leukemia inhibitory factor. Endocr Rev. 1991 Aug; 12(3):208-17. PMID: 1935819.
        View in: PubMed
      606. Kurzrock R, Talpaz M, Gomez JA, Estey EH, O'Brien S, Hirsch-Ginsberg C, Koller C, Freireich EJ, Gutterman JU. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. Br J Haematol. 1991 Jul; 78(3):352-8. PMID: 1873220.
        View in: PubMed
      607. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991 Jul; 9(7):1241-50. PMID: 2045865.
        View in: PubMed
      608. Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol. 1991 Jun; 19(5):347-51. PMID: 1709108.
        View in: PubMed
      609. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991 May; 90(5):606-13. PMID: 2029018.
        View in: PubMed
      610. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991 Apr 1; 114(7):532-8. PMID: 2001086.
        View in: PubMed
      611. Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol. 1991 Mar; 77(3):291-5. PMID: 2012752.
        View in: PubMed
      612. Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia. 1991 Mar; 5(3):191-5. PMID: 2013978.
        View in: PubMed
      613. Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer. 1991 Feb 15; 67(4):990-6. PMID: 1825026.
        View in: PubMed
      614. Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU. Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. Leukemia. 1991 Feb; 5(2):101-7. PMID: 2020193.
        View in: PubMed
      615. Dhingra K, Talpaz M, Riggs MG, Eastman PS, Zipf T, Ku S, Kurzrock R. Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias. Blood. 1991 Jan 15; 77(2):238-42. PMID: 1985690.
        View in: PubMed
      616. Kurzrock R, Estrov Z, Talpaz M, Gutterman JU. Cytokines in tumor therapy. Interleukin-3. Am J Clin Oncol. 1991; 14 Suppl 1:S45-50. PMID: 2048564.
        View in: PubMed
      617. Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, Kurzrock R. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med. 1990 Nov; 89(5):663-72. PMID: 2239986.
        View in: PubMed
      618. Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M. Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. Cancer Res. 1990 Sep 15; 50(18):5801-5. PMID: 2203522.
        View in: PubMed
      619. Cohen PR, Kurzrock R. Treatment of Sweet's syndrome. Am J Med. 1990 Sep; 89(3):396. PMID: 2203266.
        View in: PubMed
      620. Farmer KL, Kurzrock R, Gutterman JU, Duvic M. Necrotizing vasculitis at granulocyte-macrophage-colony-stimulating factor injection sites. Arch Dermatol. 1990 Sep; 126(9):1243-4. PMID: 2204310.
        View in: PubMed
      621. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Update on therapeutic options for chronic myelogenous leukemia. Semin Hematol. 1990 Jul; 27(3 Suppl 4):31-6. PMID: 2197731.
        View in: PubMed
      622. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol. 1990 Jul; 27(3 Suppl 3):15-24. PMID: 2198660.
        View in: PubMed
      623. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990 May 15; 75(10):1928-31. PMID: 1692487.
        View in: PubMed
      624. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 May 1; 75(9):1766-9. PMID: 2184901.
        View in: PubMed
      625. Kantarjian HM, Kurzrock R, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):389-404. PMID: 2182598.
        View in: PubMed
      626. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood. 1990 Jan 15; 75(2):445-52. PMID: 2403827.
        View in: PubMed
      627. Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol. 1990; 83(3):149-51. PMID: 2109455.
        View in: PubMed
      628. Cohen PR, Kurzrock R. Chronic myelogenous leukemia and Sweet syndrome. Am J Hematol. 1989 Oct; 32(2):134-7. PMID: 2667344.
        View in: PubMed
      629. Kurzrock R, Feinberg B, Talpaz M, Saks S, Gutterman JU. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. J Interferon Res. 1989 Aug; 9(4):435-44. PMID: 2502584.
        View in: PubMed
      630. Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. J Clin Oncol. 1989 May; 7(5):669-78. PMID: 2651581.
        View in: PubMed
      631. Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med. 1989 May; 86(5):554-8. PMID: 2712063.
        View in: PubMed
      632. Cohen PR, Kurzrock R. Diagnosing the Sweet syndrome. Ann Intern Med. 1989 Apr 1; 110(7):573-4. PMID: 2923392.
        View in: PubMed
      633. Cohen PR, Almeida L, Kurzrock R. Acute febrile neutrophilic dermatosis. Am Fam Physician. 1989 Mar; 39(3):199-204. PMID: 2646883.
        View in: PubMed
      634. Kurzrock R, Talpaz M, Gutterman U. Biological molecules in the treatment of hematological disorders. Sangre (Barc). 1989 Feb; 34(1):53-8. PMID: 2469130.
        View in: PubMed
      635. Kurzrock R, Gutterman JU, Kantarjian H, Talpaz M. Therapy of chronic myelogenous leukemia with interferon. Cancer Invest. 1989; 7(1):83-91. PMID: 2472193.
        View in: PubMed
      636. Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med. 1989 Jan; 149(1):105-9. PMID: 2643412.
        View in: PubMed
      637. Talpaz M, Kurzrock R, Kantarjian H, Gutterman J. Therapy of chronic myelogenous leukaemia with interferons. Cancer Surv. 1989; 8(4):793-8. PMID: 2701727.
        View in: PubMed
      638. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:63. PMID: 2496883.
        View in: PubMed
      639. Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol. 1988 Dec; 6(12):1887-97. PMID: 3058878.
        View in: PubMed
      640. Kantarjian HM, Shtalrid M, Kurzrock R, Blick M, Dalton WT, LeMaistre A, Stass SA, McCredie KB, Gutterman J, Freireich EJ. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med. 1988 Nov; 85(5):639-44. PMID: 3189367.
        View in: PubMed
      641. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988 Oct 13; 319(15):990-8. PMID: 3047582.
        View in: PubMed
      642. Cohen PR, Kurzrock R. Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol. 1988 Oct; 19(4):762-3. PMID: 3183099.
        View in: PubMed
      643. Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K, Trujillo J, Schachner J, Gutterman JU, Kurzrock R. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol. 1988 Oct; 6(10):1569-75. PMID: 3171624.
        View in: PubMed
      644. Eisbruch A, Blick M, Evinger-Hodges MJ, Beran M, Andersson B, Gutterman JU, Kurzrock R. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer. 1988 Sep 15; 62(6):1171-8. PMID: 3044574.
        View in: PubMed
      645. Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. Am J Hematol. 1988 Sep; 29(1):1-4. PMID: 3140655.
        View in: PubMed
      646. Nowell PC, Jackson L, Weiss A, Kurzrock R. Historical communication: Philadelphia-positive chronic myelogenous leukemia followed for 27 years. Cancer Genet Cytogenet. 1988 Aug; 34(1):57-61. PMID: 3165050.
        View in: PubMed
      647. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood. 1988 Aug; 72(2):485-90. PMID: 3165294.
        View in: PubMed
      648. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988 Aug; 6(8):1328-34. PMID: 3411344.
        View in: PubMed
      649. ar-Rushdi A, Negrini M, Kurzrock R, Huebner K, Croce CM. Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region. Oncogene. 1988 Apr; 2(4):353-7. PMID: 3283653.
        View in: PubMed
      650. Talpaz M, Kurzrock R, Kantarjian HM, Gutterman JU. Recent advances in the therapy of chronic myelogenous leukemia. Important Adv Oncol. 1988; 297-321. PMID: 3042607.
        View in: PubMed
      651. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol. 1988 Jan; 25(1):62-73. PMID: 2450402.
        View in: PubMed
      652. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood. 1987 Nov; 70(5):1584-8. PMID: 3311207.
        View in: PubMed
      653. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood. 1987 Oct; 70(4):943-7. PMID: 3115339.
        View in: PubMed
      654. Kurzrock R, Auber M, Mavligit GM. Cimetidine therapy of herpes simplex virus infections in immunocompromised patients. Clin Exp Dermatol. 1987 Sep; 12(5):326-31. PMID: 3446417.
        View in: PubMed
      655. Kurzrock R, Shtalrid M, Gutterman JU, Koller CA, Walters R, Trujillo JM, Talpaz M. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. Br J Haematol. 1987 Sep; 67(1):55-9. PMID: 3478080.
        View in: PubMed
      656. Blick M, Romero P, Talpaz M, Kurzrock R, Shtalrid M, Andersson B, Trujillo J, Beran M, Gutterman J. Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987 Aug; 27(2):349-56. PMID: 3474057.
        View in: PubMed
      657. Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood. 1987 Jul; 70(1):233-6. PMID: 2885048.
        View in: PubMed
      658. Cohen PR, Kurzrock R. Sweet's syndrome and malignancy. Am J Med. 1987 Jun; 82(6):1220-6. PMID: 3300306.
        View in: PubMed
      659. Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. Am J Hematol. 1987 Apr; 24(4):341-50. PMID: 3494396.
        View in: PubMed
      660. Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, Arlinghaus RB, Kouttab NM, Keating MJ, Gutterman JU. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res. 1987 Mar 15; 47(6):1731-9. PMID: 2434223.
        View in: PubMed
      661. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod. 1987 Feb; 6(1):20-7. PMID: 3104544.
        View in: PubMed
      662. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987 Feb 12-18; 325(6105):631-5. PMID: 3543692.
        View in: PubMed
      663. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol. 1987; 78 Suppl 1:70-4. PMID: 2449026.
        View in: PubMed
      664. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU. Phase I study of i.v. administered recombinant gamma interferon in cancer patients. Cancer Treat Rep. 1986 Dec; 70(12):1357-64. PMID: 3098417.
        View in: PubMed
      665. Kurzrock R, Blick MB, Talpaz M, Velasquez WS, Trujillo JM, Kouttab NM, Kloetzer WS, Arlinghaus RB, Gutterman JU. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann Intern Med. 1986 Nov; 105(5):673-9. PMID: 3094418.
        View in: PubMed
      666. Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. J Clin Oncol. 1986 Nov; 4(11):1677-83. PMID: 3095504.
        View in: PubMed
      667. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 1986 Oct; 46(10):5401-5. PMID: 3093063.
        View in: PubMed
      668. Kurzrock R, Rohde MF, Quesada JR, Gianturco SH, Bradley WA, Sherwin SA, Gutterman JU. Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med. 1986 Oct 1; 164(4):1093-101. PMID: 3093625.
        View in: PubMed
      669. Liang JC, Kurzrock R, Gutterman JU, Gallick GE. Trisomy 12 correlates with elevated expression of p21 ras in a human adenosquamous carcinoma of the lung. Cancer Genet Cytogenet. 1986 Oct; 23(2):183-8. PMID: 3530433.
        View in: PubMed
      670. Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA, Gutterman JU. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986 Jul; 4(7):1101-9. PMID: 3088221.
        View in: PubMed
      671. Kurzrock R, Gallick GE, Gutterman JU. Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res. 1986 Mar; 46(3):1530-4. PMID: 3002619.
        View in: PubMed
      672. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 Feb; 4(2):234-43. PMID: 2418169.
        View in: PubMed
      673. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 1985 Jun; 45(6):2866-72. PMID: 3921249.
        View in: PubMed
      674. Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU. Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A. 1985 Mar; 82(6):1795-9. PMID: 3885218.
        View in: PubMed
      675. Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology. 1985 Jan 30; 140(2):230-8. PMID: 2982232.
        View in: PubMed
      676. Kurzrock R, Yap BS, Plager C, Papdopoulos N, Benjamin RS, Valdivieso M, Bodey GP. Phase II evaluation of PALA in patients with refractory metastatic sarcomas. Am J Clin Oncol. 1984 Aug; 7(4):305-7. PMID: 6741860.
        View in: PubMed
      677. Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med. 1984 Jul; 77(1):35-40. PMID: 6430082.
        View in: PubMed
      678. Kurzrock R, Zander A, Kanojia M, Vellekoop L, Spitzer G, Jagannath S, Schell S, Peters L, Dicke K. Obstructive lung disease after allogeneic bone marrow transplantation. Transplantation. 1984 Feb; 37(2):156-60. PMID: 6364498.
        View in: PubMed